Adult height in girls with idiopathic central precocious puberty treated with triptorelin
Corripio, Raquel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Soriano-Guillén, Leandro (Universidad Autónoma de Madrid)
Herrero Espinet, Francisco Javier (Hospital Sant Jaume de Calella (Calella, Catalunya))
Castro-Feijoó, Lidia (Universidade de Santiago de Compostela 8santiago de Compostel·la, Galícia))
Escribano, Aránzazu (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia))
Ventura-Wichner, Paula S (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Espino, Rafael (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Vela, Amaia (Hospital Universitario de Cruces (Barakaldo, País Basc))
Labarta, José Ignacio (Hospital Universitario Miguel Servet (Saragossa))
Argente, Jesús (Universidad Autónoma de Madrid)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Objective: Idiopathic central precocious puberty (CPP) precipitates epiphyseal fusion of growth plates in long bones, leading to reduced adult stature. Gonadotropin-releasing hormone analogues (GnRHa) are the treatment of choice for idiopathic CPP, but their benefit on height gain is unclear. We aimed to elucidate the effects of GnRHa treatment on adult height in girls with idiopathic CPP. Design: This prospective observational descriptive study analyzed data of girls with idiopathic CPP diagnosed at 55 centers in Spain between January 1, 1998 and December 31, 2012 included in the Spanish Society for Pediatric Endocrinology's national registry. Methods: We included girls with idiopathic CPP (thelarche < 8 years, positive LHRH stimulation test, bone age > 1 year older than chronological age, and normal brain imaging) treated with triptorelin (3. 75 mg monthly, adjusted according to LHRH test results and clinical findings). We assessed weight, height, BMI, and secondary sexual characteristics every 6 months and bone age every 12 months until adult height (AH) was attained. The primary outcome was the difference between AH and target height (TH). Results: A total of 465 girls (18. 90% adopted) were included; we analyzed data recorded at treatment end in 358 girls and at AH in 216. Mean difference between AH and TH was -1. 5 (95%CI: -2. 56− -0. 45) cm and between AH and PAH 2,57 (95%CI:-3. 56− -1. 58) cm. Conclusions: GnRHa treatment helps preserve genetic growth potential in girls with idiopathic CPP.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Adult height ; Central precocious puberty ; CPP ; Girls ; GnRH agonists ; GnRHa ; Idiopathic central precious puberty ; Target height
Published in:	Frontiers in endocrinology, Vol. 15 (2024) , p. 1498726, ISSN 1664-2392

DOI: 10.3389/fendo.2024.1498726
PMID: 39703867

9 p, 975.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles